Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Peter G Rose

doi:10.1016/j.gore.2023.101311

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report

Gynecol Oncol Rep. 2023 Nov 28:50:101311. doi: 10.1016/j.gore.2023.101311. eCollection 2023 Dec.

Author

Peter G Rose¹

Affiliation

¹ Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, A-81, 9500 Euclid Ave., Cleveland, OH 44195, USA.

Abstract

•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression.

Publication types

Case Reports